Alessa Therapeutics Announces FDA Fast Track Designation for Enolen, a First-of-Its-Kind Treatment for Localized Prostate Cancer

Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.